Attorney Docket No. 1046.1299



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of:

Application No.: 10/656,194

Group Art Unit: To be Assigned

Filed: September 8, 2003

Examiner: To be Assigned

For: E-MAIL MANAGEMENT SYSTEM, MAIL SERVER, FORWARDING METHOD AND

MEDIUM

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 CFR § 1.56, there is hereby provided certain information which the Evaminer may consider material to the examination of

Enclosures accompanying this Information Disclosure Statement are: 1a.	of -
Copies of IDS citations. An English language copy of search report(s) from a counterpart foreig application or a PCT International Search Report. Searc	
(Check either Item 2a or 2b or 2c or 2d) 2a. Within three months of the filing date of a national application other that Continued Prosecution Application under § 1.53(d); 2b. Within three months of the date of entry of the national stage as set for § 1.491 in an international application.	to
Within three months of the filing date of a national application other the Continued Prosecution Application under § 1.53(d); Within three months of the date of entry of the national stage as set fo § 1.491 in an international application.	
2b. Within three months of the date of entry of the national stage as set fo § 1.491 in an international application.	n a
	th in
2d. Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.	r

Serial No.: 10/656,194

3.	his Information Disclosure Statement is filed under 37 CFR § 1.97(c) after the period pecified in paragraph 2 above but before the mailing date of any of a Final Office ction under § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise loses prosecution in the application, AND (Check either Item 3a or 3b; Item 3b to be checked if any reference known for more than 3 months) 3a.
4.	his Information Disclosure Statement is filed under 37 CFR §1.97(d) after the period pecified in paragraph 3 above, but on or before payment of the Issue Fee, AND 4a. The §1.97(e) Statement in Item 5 below is applicable; AND 4b. The \$1.900 fee set forth in 37 C.F.R. §1.17(p) is: enclosed. to be charged to Deposit Account No. 19-3935.
5.	statement under § 1.97(e) (applicable if Item 3a or Item 4a is checked)
	(Check either Item 5a or 5b)
	5a. In accordance with 37 CFR § 1.97(e)(1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	5b. In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
6.	his is a continuation/divisional/continuation-in-part application under 37 CFR \S .53(b).
	(Check appropriate Items 6a and/or 6b)
	Copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR § 1.98(d).
	6b. Copies of the publications listed on the attached Form PTO-1449 which were not previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, are provided herewith.

Serial No.: 10/656,194

7.		This is a Continue	continuation/divisional application under 37 CFR § 1.53(d) or a Request for d Examination under 37 CFR 1.114.	
			(Check either Item 7a or 7b)	
		7a. 7b.	The Issue Fee has not been paid. A Petition to Withdraw from issue under 37 CFR § 1.313(c) is filed concurrently herewith or has been granted. A continuation/divisional application under 37 CFR § 1.53(d) or a Request for Continued Examination under 37 CFR 1.114, after payment of the Issue Fee, is proper in accordance with 37 CFR § 1.53(d)(1)(ii) or 37 CFR 1.114(a), respectively.	
8.		This is a	Supplemental Information Disclosure Statement. (Check either Item 8a or 8b)	
		8a. 🗌	This Supplemental Information Disclosure Statement under 37 CFR § 1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental IDS can	
		8b. 🗌	be considered as if properly filed on This Supplemental Information Disclosure Statement is timely filed within one (1) month of the Notice under 37 CFR § 1.97 and 1.98, mailed	
9.			nce with 37 CFR § 1.98, a concise explanation of what is presently to be the relevance of each non-English language publication is: (Check appropriate Items 9a, 9b, 9c and/or 9d)	
		9a. 🗌	satisfied because all non-English language publications were cited on the enclosed "English language version of the search report or action which indicates the degree of relevance found by the foreign office". (See MPEP § 609, Minimum Requirements for an Information Disclosure Statement, Part A(3): Concise Explanation of Relevance, 8th Ed.)	
		9b. □ 9c. ⊠	set forth in the application. satisfied because an English language translation (complete or relevant	
		9d. 🔲	portion(s)) is attached to each non-English language publication. enclosed as Attachment 1(e), hereto.	
10.	be th	e, material an search	on is made that the information cited in this Statement is, or is considered to to patentability nor a representation that a search has been made (other report(s) from a counterpart foreign application or a PCT International ort, if submitted herewith). 37 CFR §§ 1.97(g) and (h).	

Serial No.: 10/656,194

 The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement to Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

Dated: Dec. 16 2003 1201 New York Ave., N.W., Suite 700

Washington, D.C. 20005 Telephone: (202) 434-1500 Facsimile: (202) 434-1501 Gene M. Garner II Registration No. 34,172

E ver						FIRST NAMED INVENTOR				
LIST OF	F REFERENCES CITED BY APPL				CANT	l	su NAK			
(Use several sheets if necessary)						FILING DA		GROUP ART	UNIT	
						Septe	nber 8, 2	To be As	To be Assigned	
& TRADENAM			TENT D	OCUME	VTS					
*EXAMINER DOCUMENT NO. DATE									SUB-	FILING
				NAME			CL	ASS	CLASS	DATE
	AA			-						
	AB									
	AC						+			
	AD						-			
-	AE									
	AF				-					
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NO.	DATE		COUNTR	OUNTRY (SUB- CLASS	TRANSLA YES	N
	AG	9-200256	07/31/97		JAPAN				Partial Translation	on
	AH	3036604	02/05/97		JAPAN				Partial Translation	nn n
	Al	11-331243	11/03/99		JAPAN				Abstract	
	AJ	2000-194618	07/14/00		JAPAN			 	Abstract	-
	AK							-	only	
	AL									
	AL									
OT: 150 D.							_, ,		[TDAN	OL ATIO
OTHER RE	FEREN	ICES (Including	Author, III	ie, Date	, Pertinei	nt Page	s, Etc.)		YES	SLATIC
	AM	Ī —								\top
EXAMINE	2				DATE C	ONSID	FRFD			
		aruk Hamza/								
					08/	15/2008				

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 1046 1299

FORM PTO-1449

Sheet 1 of 1

10/656 194

ATTORNEY DOCKET NO.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.